InvestorsHub Logo
Followers 58
Posts 3936
Boards Moderated 0
Alias Born 04/23/2013

Re: None

Wednesday, 05/08/2024 12:10:08 PM

Wednesday, May 08, 2024 12:10:08 PM

Post# of 425865
Over 1 billion people worldwide suffer from migraines. A new trial completed in Taiwan using 1.8g EPA/day vs. placebo demonstrated significant improvement in frequency of attacks and in the severity of those events. Another huge potential Indication for VASCEPA/VAZKEPA.
Here's a summary slide I put together showing the Primary Outcome Measures:

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News